Different antibodies can bind to the same targets on the surface of immune cells with opposite biologic effects. These effects-agonism, antagonism, or partial agonism-are so poorly understood that drug developers must screen antibodies for relevant desired characteristics. In this issue of Immunity, Lippert et al. define molecular mechanisms that dictate antibody behavior, ushering in an era of directed antibody design.
Copyright © 2024 Elsevier Inc. All rights reserved.